CNS Disorders  >>  galantamine hydrobromide  >>  Phase 3
Welcome,         Profile    Billing    Logout  

27 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
galantamine hydrobromide / Generic mfg.
NCT00338117: Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease

Completed
3
554
US
Galantamine hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Shire
Alzheimer's Disease, Dementia
 
05/97
NCT00253201: A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Completed
3
636
US
galantamine hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease, Dementia
 
10/97
NCT00253188: A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Completed
3
653
US
galantamine hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease, Dementia
 
12/98
NCT00253227: A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Completed
3
387
US
galantamine hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease, Dementia
 
12/98
NCT00309725: A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.

Completed
3
139
US
galantamine
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease
 
10/99
NCT00261573: A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia

Completed
3
593
US
galantamine hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease, Vascular Dementia
 
12/00
Extension INT-8, NCT00304629: Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease

Completed
3
241
US
galantamine
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease
 
03/02
NCT00253214: Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

Completed
3
973
US
galantamine hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease, Dementia
 
07/02
NCT00035191: A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia

Completed
3
254
US
galantamine
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dementia, Vascular
 
09/03
NCT00236574: A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Completed
3
974
US
Galantamine hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dementia, Alzheimer Disease
 
11/03
NCT00236431: A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Completed
3
1063
US
Galantamine hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dementia, Alzheimer Disease
 
12/03
NCT00301574: An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.

Completed
3
398
Japan
galantamine
Janssen Pharmaceutical K.K.
Alzheimer Disease
 
02/04
NCT00240695: A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment

Completed
3
724
US
galantamine hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases
 
05/04
NCT00230997: Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies

Completed
3
50
US
Galantamine
Neurological Research Center, Ortho-McNeil Neurologics, Inc.
Lewy Body Disease
 
08/04
NCT00645190: A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease

Completed
3
215
RoW
Galantamine HBr
Xian-Janssen Pharmaceutical Ltd.
Alzheimer Disease
 
02/05
NCT00000172: Evaluation of Galantamine in the Treatment of Alzheimer's Disease

Completed
3
US
Galantamine
Janssen, LP
Alzheimer Disease
 
 
NCT00216502: A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

Completed
3
254
Europe
galantamine hydrobromide
Janssen-Cilag S.p.A.
Alzheimer Disease, Dementia, Mental Disorders, Brain Diseases
 
11/05
NCT00216593: Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Completed
3
415
Europe
galantamine hydrobromide
Janssen Pharmaceutica N.V., Belgium
Dementia, Alzheimer Disease
09/07
03/08
Galantamine, NCT00566735: The Use of HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

Completed
3
39
US
Razadyne, Galantamine, Placebo
Massachusetts General Hospital, Ortho-McNeil Janssen Scientific Affairs, LLC
Major Depression, Bipolar Depression, Schizoaffective Disorder
01/08
01/08
NCT00814801: An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease

Completed
3
580
Japan
Placebo, Galantamine 16 mg/day, Galantamine 24 mg/day
Janssen Pharmaceutical K.K.
Alzheimer's Disease
09/08
09/08
NCT00679627: A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease

Terminated
3
2051
Europe, RoW
Galantamine, Placebo
Janssen Research & Development, LLC
Alzheimer's Disease
04/12
05/12
NCT02035982: Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease

Completed
3
40
Canada
Cholinesterase Inhibitor, Galantamine, Donepezil, Rivastigmine, Placebo
Sunnybrook Health Sciences Centre
Alzheimer's Disease, Dementia
05/14
09/15
2007-002780-27: A double-blind, placebo-controlled, 2-year study of galantamine used to treat patients with Mild to Moderate Alzheimer\'s disease.

 
3
420
Europe
Galantamine HBr, R113675, REMINYL 8mg prolonged-release capsules, hard (REMINYL 1x täglich 8mg Hartkapseln, retardiert), REMINYL 16mg prolonged-release capsules, hard (REMINYL 1x täglich 16mg Hartkapseln, retardiert), REMINYL 24mg prolonged-release capsules, hard (REMINYL 1x täglich 24mg Hartkapseln, retardiert), REMINYL 8mg prolonged-release capsules, hard (REMINYL 1x täglich 8mg Hartkapseln, retardiert), REMINYL 16mg prolonged-release capsules, hard (REMINYL 1x täglich 16mg Hartkapseln, retardiert), REMINYL 24mg prolonged-release capsules, hard (REMINYL 1x täglich 24mg Hartkapseln, retardiert)
Janssen Cilag International NV, Janssen-Cilag International, Johnson & Johnson Pharmaceutical Research and Development LLC,
Mild to moderately severe Alzheimer\'s Disease
 
03/12
NCT02374567: Pharmacovigilance in Gerontopsychiatric Patients

Terminated
3
407
Europe
Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine, Valproic Acid, Lamotrigine, Topiramate, Gabapentin, Levetiracetam, Pregabalin, Lacosamide, Clonazepam, Biperiden, Levomepromazine, Fluphenazine, Perphenazine, Perazine, Thioridazine, Haloperidol, Melperone, Pipamperone, Bromperidol, Benperidol, Sertindole, Ziprasidone, Flupentixol, Chlorprothixene, Zuclopenthixol, Fluspirilene, Pimozide, Clozapine, Olanzapine, Quetiapine, Sulpiride, Tiapride, Amisulpride, Prothipendyl, Risperidone, Aripiprazole, Paliperidone, Diazepam, Oxazepam, Lorazepam, Bromazepam, Clobazam, Alprazolam, Hydroxyzine, Buspirone, Chloral Hydrate, Flurazepam, Nitrazepam, Triazolam, Lormetazepam, Temazepam, Midazolam, Brotizolam, Zopiclone, Zolpidem, Zaleplon, Melatonin, Clomethiazole, Diphenhydramine, Promethazine, Imipramine, Clomipramine, Opipramol, Trimipramine, Amitriptyline, Nortriptyline, Doxepin, Maprotiline, Amitriptyline oxide, Fluoxetine, Citalopram, Paroxetine, Sertraline, Fluvoxamine, Escitalopram, Tranylcypromine, Moclobemide, Mianserin, Trazodone, Mirtazapine, Bupropion, Venlafaxine, Reboxetine, Duloxetine, Agomelatine, Pyritinol, Piracetam, Donepezil, Rivastigmine, Galantamine, Memantine, Nicergoline, Acamprosate, Lithium
Hannover Medical School
Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
06/17
06/17
NCT01872598 / 2010-021218-50: Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Completed
3
721
Europe, RoW
Masitinib, AB1010, Placebo, Placebo Oral Tablet, Standard of care
AB Science
Alzheimer Disease
12/20
12/20
NCT00463879: Galantamine for Cognitive Deficits in Schizophrenia

Completed
2/3
21
US
Galantamine
Yale University, National Alliance for Research on Schizophrenia and Depression
Schizophrenia
 
09/07
STREAM-VCI, NCT02098824: Symptomatic Treatment of Vascular Cognitive Impairment

Unknown status
2/3
30
Europe
Galantamine, Reminyl, Methylphenidate, Ritalin, Placebo
Amsterdam UMC, location VUmc
Mild Cognitive Impairment (Vascular), Mild Cognitive Disorder (Vascular), Vascular Dementia
12/16
07/17

Download Options